Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection

NCT01721694 | Withdrawn Phase 3

• 2 other identifiers: AZILOT-12131.835
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or conjunctivitis compared with the individual administration of azithromycin 1.5% and 0.5% Loteprednol (separately).

Conditions

Ocular Inflammation; Infection Associated Blepharitis; Keratitis; Conjunctivitis, Bacterial

Keywords

bacterial ocular inflammation; blepharitis; keratitis; conjunctivitis

Outcome Measures

Primary Outcomes (1)

• Clinical cure

  Clinical cure achieved when the score of the cardinal ocular signs (hyperemia in the bulbar conjunctiva, palpebral, exudate / conjunctival discharge, eyelid erythema and flaking / crust eyelid) is zero at the time of conclusion of the study (D8)

  Day 8

Secondary Outcomes (1)

• irradication of pathogens

  Day 8

Other Outcomes (1)

• ophthalmic evaluation

  Day 4 and Day 8

Study Arms (2)

azithromycin 1.5%/Loteprednol 0,5% + placebo

EXPERIMENTAL

fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops

Drug: azithromycin 1.5%/Loteprednol 0,5% + placebo

azithromycin 1.5% + Loteprednol 0,5% (separately)

ACTIVE COMPARATOR

azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)

Drug: azithromycin 1.5% + Loteprednol 0,5% (separately)

Interventions

azithromycin 1.5%/Loteprednol 0,5% + placebo DRUG

1 drop, AO, QID

azithromycin 1.5%/Loteprednol 0,5% + placebo

azithromycin 1.5% + Loteprednol 0,5% (separately) DRUG

1 drop, QID, AO

Also known as: azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)

azithromycin 1.5% + Loteprednol 0,5% (separately)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients were male or female, of any race and age minimum of 18 years.
• Blepharitis should provide diagnostic and / or keratitis and / or conjunctivitis with or without bacterial involvement corneal by biomicroscopy, with positive staining corneal fluorescein and also provide a composite score ≥ 2 on: bulbar conjunctival hyperemia, eyelid conjunctiva, secretion / exudate conjunctival erythema and flaking eyelids / eyelid crust on at least one eye (the same eye) on Day 1 visit

You may not qualify if:

• Intraocular hypertension or uncontrolled glaucoma.
• Use of contact lenses during the study.
• Capacity unilateral visual only.
• Suspected fungal infection, viral (eg, herpes simplex epithelial, dendritic keratitis) or Acanthamoeba, or any other disease where the use of corticosteroids is contraindicated.
• Use of any topical ophthalmic medications preserved during study participation. Not be allowed eyedrops preserved (eg artificial tears).
• Use of any antibacterial agent oral or topical ophthalmic until 72 hours prior to study entry.
• Use of systemic steroids within 14 days prior to study entry. Ophthalmic topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs), until one week before admission to the study. Will not be allowed to use these medications during study participation. Will not be allowed to use nasal steroids during the study. Will be allowed to use inhaled steroids to aid inhaler. Will be allowed steroids dermal topics.
• Use of nonsteroidal anti-inflammatory drugs (NSAIDs) systemic up to 24 hours prior to study entry or at any time during the study, unless the patient is under treatment regimen with stable (not necessary) for at least 2 months before Admission and therapy continues throughout the study.
• Any disturbance or ocular or systemic disease, complicating factors or structural abnormality that affects the conduct or outcome of the study in a negative way or represents an undue risk to patient safety, according to the opinion of the investigator.
• Any current immunosuppressive disorder (eg, HIV-positive), or immunosuppressive therapy (including chemotherapy).
• Known allergy or suspected allergy or hypersensitivity to fluoroquinolones, to steroids or any other component of the study drug;
• Pregnant or lactating. (Women of childbearing age may be admitted if they use contraception and submit urine pregnancy test negative);
• Any patient who has a family member who participates in this study

Sponsors & Collaborators

• Adapt Produtos Oftalmológicos Ltda.: lead

Study Sites (1)

Department of Ophthalmology of Hospital São Paulo

São Paulo, São Paulo, 04023-062, Brazil

Location

MeSH Terms

Conditions

Keratitis; Conjunctivitis, Bacterial; Blepharitis; Conjunctivitis

Interventions

Azithromycin

Condition Hierarchy (Ancestors)

Corneal Diseases; Eye Diseases; Eye Infections, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Eye Infections; Conjunctival Diseases; Eyelid Diseases

Intervention Hierarchy (Ancestors)

Erythromycin; Macrolides; Polyketides; Lactones; Organic Chemicals

Study Officials

• Rubens Belfort Jr., MD

  Federal University of São Paulo / Hospital São Paulo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 2012
• First Posted: November 6, 2012
• Study Start: December 1, 2012
• Primary Completion: March 1, 2013
• Study Completion: May 1, 2013
• Last Updated: December 11, 2014

Record last verified: 2014-12

Locations

BR (1)